China's CARsgen Therapeutics Holdings, a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr Raffaele Baffa has been appointed as the Chief Medical Officer (CMO) of the Company, responsible for overseeing the global clinical development strategies and operations for the Company's innovative pipeline product candidates. Dr Baffa will report to Dr Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited.

Dr Baffa has rich experiences in pharmaceutical industry and research institutes, taking various leadership positions in multi-national corporations and biotech companies.

Prior to joining CARsgen, Dr Baffa served as Chief Medical Officer and Executive Vice President of Research & Development at Ziopharm Oncology, which was rebranded to Alaunos in January 2022. Prior to Ziopharm Oncology, Dr Baffa was Head of Research & Development and Chief Medical Officer in Medisix Therapeutics, a company focused on developing novel immune cell therapies.

Dr Baffa was the Vice President, Therapeutic Area Head of Oncology, Global Clinical Development of Shire Pharmaceuticals, and following the acquisition of the oncology division by Servier Pharmaceuticals, Dr Baffa served as the Chief Medical Officier of Servier Pharmaceuticals. Dr Baffa has also held leadership positions at well-known pharmaceutical companies, such as Pfizer and Sanofi.

Dr Baffa earned an M.D. from University of Padova, School of Medicine and a Ph.D. in biology and molecular pathology from University of Parma in Italy.